Straumann Group Reports Strong Start in 2024 with Impressive Regional Growth

Straumann Holding AG announced a robust beginning to 2024, registering a significant organic revenue increase of 15.1%, bringing the first-quarter revenue to CHF 643.8 million. The Asia Pacific region, particularly China, demonstrated Outstanding performance, contrasting with the more modest results in North America and Europe due to various macroeconomic factors.

Notably, the company launched two major products this quarter - the iEXCEL premium implant system in North America and the AlliedStar intraoral scanner in China - underscoring its commitment to innovation and market expansion. Despite the forecast of challenging macroeconomic conditions, Straumann confirmed its 2024 outlook, aiming for high single-digit organic revenue growth and a profitability rate of around 26%.

Revenue data illustrated disparate regional dynamics. The Asia Pacific region's revenue soared by 82.0% organically, fueled by a low comparative base from the previous year when patient flows were disrupted by COVID-19. Meanwhile, North America and Europe reported modest gains of 3.7% and 5.2% respectively in organic growth, impacted by high interest rates and strong prior year comparisons.

The company's strategic progress remains strong, with significant initiatives like the iEXCEL system in North America enhancing clinical procedures through unified prosthetic platforms and simplified workflows, and the introduction of the intraoral scanner in China promising greater penetration into digital dentistry.